Lycelle Head Lice Removal Kit Now Available without Rx

Mission Pharmacal announced that Lycelle Head Lice Removal Kit (sodium laureth sulfate, isopropanol, citronellyl acetate, hypromellose, methyl salicylate, methylparaben, citric acid) is now available without a prescription.

Taltz Now Available for Moderate-to-Severe Plaque Psoriasis

Eli Lilly announced that Taltz (ixekizumab) injection is now available for the treatment of moderate-to-severe plaque psoriasis through a network of specialty pharmacies.

Which Drugs Are Most Associated With Stevens-Johnson Syndrome?

New findings from a study published in the American Journal of Medicine may help clinicians identify high-risk drugs and high-risk patients linked to the development of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) in order to reduce its incidence.

Positive Results Announced for Dupilumab in Atopic Dermatitis Studies

Regeneron and Sanofi announced that the two Phase 3 studies, LIBERTY AD SOLO 1 and SOLO 2, evaluating dupilumab for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD), met their primary endpoints.

Aczone 5% Gel 30g Tubes Now Discontinued

Allergan announced the discontinuation of Aczone (dapsone) 5% 30g tubes.

New Biosimilar Inflectra Gets FDA Approval

The Food and Drug Administration (FDA) has approved Inflectra (infliximab-dyyb; Celltrion) for injection, a biosimilar to Remicade (infliximab; Janssen).

Skin Infection Patients Adhere to Just Over Half of Their Antibiotic Regimen, Study Finds

Patients with Staphylococcus aureus skin and soft tissue infections took an average of 57% of their antibiotic doses after being discharged from the hospital, a new study published in Antimicrobial Agents and Chemotherapy reported.

Taltz Approved for Moderate-to-Severe Plaque Psoriasis

Eli Lilly announced that the Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

New Homeopathic Wipes for Insect Bites and Stings Available

Tec Labs announced the launch of Tecnu Bites & Stings Medicated Itch and Pain Relief Wipes for treating insect bites and bee stings.

FDA to Review Novel Non-Steroidal Tx for Atopic Dermatitis

Anacor Pharmaceuticals announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) of crisaborole 2% topical ointment for the potential treatment of mild-to-moderate atopic dermatitis in children and adults.

Corticosteroid Injection Currently in Shortage

The FDA is reporting a shortage in certain presentations of Solu-Medrol Powder for Injection (Pfizer) and the generic Methylprednisolone sodium succinate for injection (Fresenius Kabi).

FDA to Review Enbrel for Pediatric Plaque Psoriasis

Amgen has announced that the U.S. Food and Drug Administration (FDA) has accepted for review their supplemental Biologics License Application (sBLA) for the expanded use of Enbrel (etanercept).

Nonsurgical Treatment Improves Appearance of Double Chin

At the American Academy of Dermatology's annual meeting, researchers presented study findings supporting the safety and efficacy of ATX-101 in reducing the appearance of a double chin.

Results for Cosentyx vs. Stelara Announced in PASI 90 Endpoint

Novartis announced late-breaking data from the CLEAR study that demonstrated Cosentyx (secukinumab) was superior to Stelara (ustekinumab) in reaching near clear skin on the PASI 90 in significantly more moderate to severe psoriasis patients at Week 52.

Long-Term Safety Data for Otezla Announced

Celgene announced long-term safety data for Otezla (apremilast) from ongoing clinical trials at the American Academy of Dermatology's Annual Meeting.

Ixekizumab Demonstrates Efficacy in Two Phase 3 Psoriasis Studies

Lilly announced positive results from two Phase 3 studies, UNCOVER-2 and UNCOVER-3, of ixekizumab for the treatment of moderate-to-severe plaque psoriasis compared to etanercept or placebo. Study findings were recently presented at the American Academy of Dermatology (AAD) Annual Meeting in Washington, D.C.

Treatment Options for Dermatoses in Pregnancy Explored

Dermatoses in pregnancy provides a challenge to dermatologists when it comes to recommending treatments that are effective yet safe to the fetus.

New OTC Dual Action System Launched for Hair Loss

Galderma announced the launch of qilib Hair Regrowth + Revitalization System and qilib Hair Health Reinforcement Biotin + Multivitamin Supplement indicated for hair thinning and hair loss

New Topical Gel Approved for Acne Vulgaris

Allergan announced that the Food and Drug Administration (FDA) has approved Aczone Gel 7.5%, a new topical treatment for acne vulgaris in patients aged ≥12 years.

New Acne Treatment Guidelines Released

The American Academy of Dermatology has released its new "Guidelines of care for the management of acne vulgaris" that includes acne treatment recommendations for adults and adolescents.

Advisory Panel Recommends Approving Biosimilar of Remicade

Celltrion announced that the Food and Drug Administration (FDA) Arthritis Advisory Committee recommended approval of all indications for CT-P13, a biosimilar candidate of Remicade (infliximab; Janssen Biotech).

New Topical Steroid Approved for Plaque Psoriasis

Dr. Reddy's announced that Promius Pharma has received approval for Sernivo (betamethasone dipropionate) Spray 0.05% for the treatment of mild to moderate plaque psoriasis in patients aged ≥18 years.

New Oral Rosacea Drug Gains Tentative FDA Approval

Dr. Reddy's Laboratories announced that the Food and Drug Administration (FDA) has granted tentative approval for Zenavod (doxycycline) capsules for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adults.

BLA for Adalimumab Biosimilar Accepted for Review

Amgen announced that the Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira (adalimumab).

BLA for New Plaque Psoriasis Tx Under FDA Review

Valeant, in partnership with AstraZeneca, announced that the Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for brodalumab injection for patients with moderate-to-severe plaque psoriasis.

Cosentyx Gains Two New Arthritis Indications

Novartis announced that the Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

Granulex Aerosol Spray Discontinued

The Food and Drug Administration (FDA) informed that Granulex Aerosol Spray (trypsin, balsam peru, castor oil; Mylan) has been discontinued due to market conditions.

FDA: Watch for Eye, Skin Injuries with Laser Pointers

The Food and Drug Administration (FDA) is alerting healthcare professionals about possible eye and skin injuries from exposure to laser-containing products.

FDA Proposes Tanning Bed Restrictions, Including Age Limits

The Food and Drug Administration (FDA) has proposed steps to prevent the use of sunlamp products by minors and to reduce the risk of these devices for adults.

New Treatment for Rosacea Launched

Bayer HealthCare announced the launch of Finacea Foam (azelaic acid) 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.

Topical Combo Treatment Approved for Plaque Psoriasis

Leo Pharma announced that Enstilar (calcipotriene and betamethasone dipropionate) foam has been approved for the topical treatment of plaque psoriasis in adults aged ≥18 years.

Complete Response Letter Issued for Xeljanz on New Indication

The FDA has issued a Complete Response Letter (CRL) for the supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate; Pfizer) for the treatment of adults with moderate to severe chronic plaque psoriasis.

New Findings for Plaque Psoriasis Tx Otezla Presented

Celgene announced that new findings from its ongoing Phase 3 LIBERATE trial evaluating Otezla (apremilast) in patients with moderate to severe plaque psoriasis were presented at the 24th European Academy of Dermatology and Venereology (EADV) Congress.

FDA Grants Avelumab Fast Track Status for Aggressive Skin Cancer

The Food and Drug Administration has granted avelumab (Pfizer/Merck) Fast Track designation for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.

Rash and Fever in Adults Could Indicate Rare But Deadly Disease

Skin rashes accompanied by a fever could be indicative of serious or life-threatening illness in adults and warrant immediate medical attention, according to a lecture to be presented at the American Osteopathic Association's Annual Osteopathic Medical Conference and Exposition (OMED).

Novel Combination Treatment Approved for Unresectable or Metastatic Melanoma

Bristol-Myers Squibb announced that the Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.

Depression Screening Recommended for Psoriasis Patients

Psoriasis patients, regardless of disease severity, may be at an increased risk of depression, according to a study recently published in JAMA Dermatology.

FDA Designates Avelumab Orphan Drug for Skin Cancer

The FDA has granted Orphan Drug designation to the investigational cancer immunotherapy avelumab (Pfizer/Merck) for the treatment of Merkel cell carcinoma (MCC).

Vinegar May Be an Effective Alternative Against Bacteria in Burn Wounds

The active ingredient in household vinegar was effective in preventing infections and killing bacteria present in burn wounds, a new study has found.

Nalbuphine ER: Promising Study Results for Uremic Pruritus

Trevi Therapeutics announced statistically significant results from its Phase 2/3 trial of Nalbuphine ER for the treatment of moderate to severe uremic pruritus.

OTC Laser Tx for Male Baldness to Be Evaluated in Study

Theradome announced that it has initiated one of the most comprehensive studies to date to evaluate its Theradome LH80 PRO Laser Helmet on men with thinning hair or who are showing signs of balding.

FDA Accepts Keytruda sBLA for First-Line Melanoma Indication

The Food and Drug Administration (FDA) has accepted for review the sBLA for Keytruda (pembrolizumab, Merck) for the first-line treatment of unresectable or metastatic melanoma patients.

FDA: Reports of Severe Allergic Reactions with Picato

The Food and Drug Administration (FDA) is warning about reports of severe allergic reactions and herpes zoster associated with the use of Picato (ingenol mebutate topical gel).

What Tests, Txs May Be Unnecessary in Dermatology?

The American Academy of Dermatology has issued new recommendations regarding potentially unnecessary dermatologic tests and treatments as part of the Choosing Wisely campaign.

Treatment-Resistant Lice Common Across the U.S.

Treatment-resistant lice with one or more genetic mutations have been identified in at least 25 states, according to research presented at the 250th National Meeting & Exposition of the American Chemical Society (ACS).

Epiduo Forte Gel Now Available for Acne Vulgaris

Galderma announced the launch of Epiduo Forte (adapalene and benzoyl peroxide) Gel for the once-daily, topical treatment of acne vulgaris.

Systemic Therapies for Pediatric Psoriasis Compared

The safety and efficacy of biologics in the treatment of pediatric psoriasis were demonstrated in several case studies published in the Journal of Drugs in Dermatology.

Physical Trauma Ups Psoriatic Arthritis Risk

Psoriasis patients who experience physical trauma have an increased risk of developing psoriatic arthritis, according to a study presented at the European League Against Rheumatism Annual Conference (EULAR 2015) in Rome.

Greater Patient Satisfaction Seen With Biologics for Psoriasis

Patients taking biologic medications are more satisfied with their treatment and prefer longer dosing intervals compared to those taking other types of medicines for moderate to severe plaque psoriasis, reports a study in Patient Preference and Adherence.

Galderma Launches Two New Acne Mask, Cleanser Products

Galderma announced the launch of two new additions to the Benzac Acne Solutions product line: Benzac Skin Refining Mask and Benzac Acne Eliminating Cleanser.

Finacea Foam Approved for Rosacea

Bayer HealthCare announced that the Food and Drug Administration (FDA) has approved Finacea (azelaic acid) Foam 15% for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea.

FDA Warns Against Harmful Ingredient in Black Henna Tattoo Ink

The Food and Drug Administration (FDA) is warning that black henna tattoos may cause harmful skin reactions in some people.

Arthritis Drug May Help Eczema Patients, Too

A drug used to treat rheumatoid arthritis (RA) was effective in patients with moderate to severe eczema, according to a study conducted by researchers from Yale School of Medicine.

New Antibiotic-Free Acne Gel Approved

Galderma announced that the Food and Drug Administration (FDA) has approved Epiduo Forte (adapalene and benzoyl peroxide) Gel 0.3%/2.5% for the once-daily topical treatment of acne vulgaris.

Survey: Significant Education Needed for Psoriasis Patients, Clinicians

At the recent 4th World Psoriasis & Psoriatic Arthritis Conference, the International Federation of Psoriasis Associations (IFPA) released the results of a global survey on significant unmet needs on the impact of psoriasis.

Review: Acupuncture as Primary Tx for Skin Disorders

In a systematic review, acupuncture was found to improve outcome measures in the treatment of dermatitis, cholasma, pruritus, urticaria, hyperhidrosis, and facial elasticity.

Probiotics May Help Reduce Sepsis Risk in Burn Patients

Patients who had suffered severe burns were found to have a huge increase in Enterobacteriaceae and a decrease in beneficial bacteria, according to a study published in PLOS ONE.

Guselkumab May Clear Plaque Psoriasis, Shows Study

Janssen Research & Development announced results from the Phase 2b X-PLORE trial with guselkumab in patients with moderate to severe plaque psoriasis.

New Steroid-Free Options for Itch Relief Launched

Cosmederm Bioscience announced the expansion of its itch-relief product line featuring two new steroid-free, anti-itch products.

FDA: Derm Dilemma with Daytrana

The Food and Drug Administration (FDA) has issued a warning that the use of Daytrana patch (methylphenidate transdermal system; Noven) may result in permanent loss of skin color.

New Insight on ED Drugs-Melanoma Risk Link

Patients taking medications for erectile dysfunction may have an increased risk of melanoma, but these drugs are not a cause of melanoma, researchers concluded.

Black Box Warning for Potiga Reviewed Again by FDA

The Food and Drug Administration (FDA) has determined that the Boxed Warning for Potiga (ezogabine; GlaxoSmithKline) is adequate to manage the potential risks of vision loss due to pigment changes in the retina and skin discoloration.

Significant Improvement in Plaque Psoriasis Seen With Cosentyx

Novartis announced results from two clinical trials on the efficacy of Costentyx (secukinumab) for the treatment of plaque psoriasis of the palms, soles, and nails in adult patients.

FDA: Beware of Embolization With Dermal Fillers

The Food and Drug Administration (FDA) has issued an alert regarding certain injection sites on the face where unintentional injection of soft tissue fillers into blood vessels in the face can result in rare but serious side effects.

Which Tattoo Ink Colors Are Most Likely to Cause Skin Reactions?

Researchers at the NYU Langone Medical Center have reported that up to six percent of adults in New York who get tattoos have experienced some form of tattoo-related rash, severe itching, or swelling that lasted from four months up to years for some.

Humira Designated Orphan Drug for Painful, Inflammatory Skin Disease

AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for Humira (adalimumab) as an investigational treatment for moderate-to-severe hidradenitis suppurativa (HS; Hurley Stage II and III disease).

Vitamin B3 May Reduce Recurrence of Some Skin Cancers in High-Risk Patients

A study presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting found that an over-the-counter form of vitamin B3 significantly reduced rates of new non-melanoma skin cancers in high-risk patients, which along with sun protection could help to decrease the health and economic burden of skin cancer.

Study: Anti-Itch Hydrogel Superior to OTC Creams

A study published in Clinical, Cosmetic, and Investigational Dermatology showed that TriCalm hydrogel is significantly superior to diphenhydramine 2 percent and hydrocortisone 1 percent in its antipruritic effect.

Opdivo sBLA Under Priority Review for New Melanoma Indication

The Food and Drug Administration (FDA) has accepted for filing and has granted Priority Review to the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) for the treatment of previously untreated patients with unresectable or metastatic melanoma.

High-Dose Creams More Effective for Genital Warts, Reports Study

A high-dose treatment of sodium nitrite and citric acid creams applied twice daily was more effective than placebo for treating anogenital warts, according to a new study in JAMA Dermatology.

New OTC Ointment Launched for Shingles Relief

Aidance Scientific announced the launch of Terrasil Shingles Skincare Ointment, a new over-the-counter treatment to soothe highly sensitive skin in patients of all ages.

Investigational Malignant Melanoma Therapy Granted Orphan Drug Status

The Food and Drug Administration (FDA) has granted Orphan Drug designation to SRX-1177 (SolaranRx) for the treatment of stage IIB to IV malignant melanoma.

Counterfeit Botox Discovered in the U.S.

The FDA is alerting healthcare providers and the public that counterfeit Botox (onabotulinumtoxin A; Allergan) has been found in the United States and may have been distributed to doctors' offices and clinics.

Samcyprone Designated Orphan Drug for Malignant Melanoma

The FDA has granted Orphan Drug designation to Samcyprone (diphenylcylcopropenone, DPCP; RXi Pharmaceuticals) for the treatment of malignant melanoma Stage IIb to IV.

No More Latex-Free Claims, Recommends FDA

The Food and Drug Administration (FDA) is recommending that manufacturers stop using the labels "latex-free" or "does not contain latex" due to the scientific inaccuracy of these claims.

Keytruda Results May Halt Melanoma Trial Early

Merck announced results from the Phase 3 KEYNOTE-006 study investigating Keytruda (pembrolizumab) vs. ipilimumab in the first-line treatment of patients with advanced melanoma.

New Data Shows Tofacitinib Effective for Plaque Psoriasis

Pfizer announced results from two Phase 3 studies from the Oral treatment Psoriasis Trials (OPT) program for tofacitinib citrate in adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Long-Term Efficacy Data for Otezla in Plaque Psoriasis Announced

Celgene announced results from the ESTEEM Phase 3 clinical program for Otezla (apremilast) in patients with moderate to severe plaque psoriasis.

Acne Medication Rxs Often Go Unfilled, Says New Survey

Over 25% of patients with acne did not obtain medications prescribed by their dermatologists, according to a survey by Wake Forest Baptist Medical Center researchers.

Combo Acne Drug Reduces Lesion Count in Trial

Galderma announced positive Phase 3 results for adapalene 0.3%/benzoyl peroxide 2.5% (0.3% A/BPO) topical gel.

Two Older Antibiotics Effective Against Community-Acquired MRSA, Says New Research

Two common antibiotics have been shown to be equally effective in treating uncomplicated community-acquired skin infections like methicillin-resistant Staphylococcus aureus (MRSA), according to a new study in the New England Journal of Medicine.

Adding BP Drug May Lessen Topical Steroid Side Effects

An antihypertensive was found to reduce side effects from corticosteroid-based creams used for certain skin diseases, reports a study published in the Journal of Investigative Dermatology.

Smart Bandage Could Prevent Bed Sores With Early Detection

A new "smart bandage" has been developed that can detect early tissue damage from pressure ulcers before they are visible to the human eye.

Psoriasis Symptoms Improve After Single Dose of Experimental Antibody Tx in Study

Patients with moderate-to-severe psoriasis showed significant recovery after a single dose of an experimental human antibody treatment that targets interleukin-23, a study showed.

First Biosimilar Product Approved by the FDA

The Food and Drug Administration (FDA) has approved the first biosimilar product, Zarxio (filgrastim-sndz; Sandoz).

Melanoma Treatment Under Review for Preventing, Delaying Recurrence

The Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Yervoy (ipilimumab; Bristol-Myers Squibb) for the adjuvant treatment of patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection.

Skin Biopsy May Help Detect Alzheimer's, Parkinson's Earlier

A skin test may help diagnose Alzheimer's and Parkinson's diseases by detecting potential biomarkers, new research has shown.

FTC Cracks Down on Melanoma Detection Apps

The Federal Trade Commission (FTC) has announced that the agency is actively challenging several marketers of mobile apps promoted to detect symptoms of melanoma (even in its early stages) due to deceptive claims.

New Data on Once-Daily Baricitinib for RA From Phase 3 Trial

Eli Lilly and Company and Incyte announced results from a second Phase 3 trial with baricitinib in patients with rheumatoid arthritis.

First Permanent Varicose Veins Tx With Adhesive Approved

The Food and Drug Administration (FDA) has approved Covidien's VenaSeal system for permanent treatment of varicose veins of the legs by sealing the affected superficial veins with an adhesive.

Cancer Risk With Eczema Drug Tracked in Long-Term Study

Treatment with pimecrolimus for eczema was found unlikely to increase the risk of cancer in children, according to a post-marketing study.

New Rosacea Tx Option Now Available

Galderma announced the availability of Soolantra (ivermectin) Cream for the the treatment of rosacea.

Xeljanz sNDA Accepted for Review for Plaque Psoriasis

The Food and Drug Administration (FDA) has accepted for review the sNDA for Xeljanz (tofacitinib citrate; Pfizer) 5mg and 10mg tablets for the treatment of adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

First Tissue Adhesive for Internal Use Approved

The Food and Drug Administration (FDA) has approved Cohera Medical's TissuGlu Surgical Adhesive, the first tissue adhesive for internal use.

First Dermal Filler Approved for Lip Enhancement, Perioral Lines

Galderma announced the launch of Restylane Silk, the first dermal filler approved for lip augmentation and correction of perioral rhytids in patients over 21 years old.

Cosentyx for Plaque Psoriasis Approved

Novartis announced that the Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Natroba Now Approved for Younger Children with Head Lice

ParaPRO announced that the Food and Drug Administration (FDA) has approved an expanded age range for Natroba (spinosad) Topical Suspension, to include children 6 months of age and older who have pediculosis capitis (head lice).

BioBag Now Available for Biosurgical Wound Debridement

BioMonde announced the launch of BioBag, a biosurgical medical device for wound debridement.

First Dermal Filler for Acne Scar Treatment Approved

Suneva Medical announced that the Food and Drug Administration (FDA) has approved Bellafill for the treatment of acne scars in patients over age 21.